Project: Secretoneurin (SN): a breakthrough blood biomarker for heart disease and sudden Cardiac Arrest risk
Acronym | SeNCA (Reference Number: 11989) |
Duration | 31/03/2018 |
Project Topic | Secretoneurin (SN) is a novel biomarker that improves risk prediction in cardiovascular disease by reflecting additional pathophysiology to established risk indices. SeNCA will bring this innovation towards market entry by developing and validating a SN ELISA and by documenting that SN identifies patients with increased risk of ventricular arrhythmias. The assay will be launched as a Research use Only (RuO) version immediately after SeNCA and as CE-marked version 12 months post-project. |
Network | Eurostars 2 |
Call | Eurostars Cut-Off 8 |